Get the Stockscreener App
2.39
2.45%
-0.06
After Hours:
2.49
0.10
+4.18%
Phio Pharmaceuticals Corp stock is traded at $2.39, with a volume of 118.43K.
It is down -2.45% in the last 24 hours and up +5.52% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$2.45
Open:
$2.5
24h Volume:
118.43K
Relative Volume:
0.17
Market Cap:
$11.47M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.293
EPS:
-8.156
Net Cash Flow:
$-11.09M
1W Performance:
-0.83%
1M Performance:
+5.52%
6M Performance:
-3.63%
1Y Performance:
-46.89%
1-Day Range:
$2.35
$2.52
1-Week Range:
$2.33
$2.52
52-Week Range:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Compare PHIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
2.39 | 11.56M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
What analysts say about Phio Pharmaceuticals Corp. stockExplosive earnings growth - Autocar Professional
What drives Phio Pharmaceuticals Corp. stock priceExplosive capital appreciation - Autocar Professional
Is Phio Pharmaceuticals Corp. a good long term investmentFree Stock Movement Tracking - Autocar Professional
Phio Pharmaceuticals Corp. Stock Analysis and ForecastDouble-digit growth - Autocar Professional
Why Phio Pharmaceuticals Corp. stock attracts strong analyst attentionHigh Reward Risk Balanced Trading - Newser
What makes Phio Pharmaceuticals Corp. stock price move sharplySmart Growth Low Risk Picks - Newser
How Phio Pharmaceuticals Corp. stock performs during market volatilityFree Financial Group - Newser
Phio Pharmaceuticals Announces 2025 Annual Meeting Details - The Globe and Mail
Phio Pharmaceuticals (NASDAQ:PHIO) Stock Price Up 6.3% – Here’s Why - Defense World
Phio Pharma stock maintains buy rating as cancer trial advances - Investing.com
Phio's Skin Cancer Drug Shows 44% Complete Response Rate, Final Trial Phase Begins - Stock Titan
Breakthrough: Phio's Skin Cancer Treatment Shows Positive Results in Phase 1b Trial, CEO Details Progress - Stock Titan
Phio Pharmaceuticals Announces Strategic Initiative and Leadership Changes - TipRanks
Phio Pharmaceuticals Appoints Lisa Carson As Principal Financial OfficerSEC Filing - MarketScreener
Research Analysts Set Expectations for PHIO FY2025 Earnings - Defense World
What is HC Wainwright’s Forecast for PHIO Q2 Earnings? - Defense World
Phio Pharmaceuticals appoints new strategic and finance VPs By Investing.com - Investing.com South Africa
Phio Pharmaceuticals appoints new strategic and finance VPs - Investing.com India
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio - TradingView
Phio Pharmaceuticals Advances 30-Drug Cancer Portfolio as Phase 1b Trial Shows Promise - Stock Titan
Phio Pharmaceuticals (NASDAQ:PHIO) Now Covered by HC Wainwright - Defense World
Phio Pharma (PHIO) Receives Buy Rating and $14 Price Target from HC Wainwright | PHIO Stock News - GuruFocus
H.C. Wainwright assumes coverage on Phio Pharma stock with Buy rating - Investing.com India
Phio Pharmaceuticals (PHIO) Gains 'Buy' Rating with Promising Pr - GuruFocus
2 No-Brainer Artificial Intelligence (AI) Stocks to Buy Right Now - The Globe and Mail
Why BioNTech Stock Soared Today - The Globe and Mail
Best Value Stocks to Buy for May 28th - The Globe and Mail
New Strong Buy Stocks for May 28th - The Globe and Mail
AI Momentum Stocks: 3 Breakout Companies (ASML, PLTR, AVGO) - The Globe and Mail
New Strong Buy Stocks For May 28th - Barchart.com
2 ‘Strong Buy’ Small-Cap Stocks With Blockbuster Potential - The Globe and Mail
Phio Pharmaceuticals (NASDAQ:PHIO) Trading 2.8% Higher – Time to Buy? - Defense World
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference - Newsfile
Phio Reveals Latest Progress on Revolutionary Cancer-Fighting siRNA Technology at Investor Conference - Stock Titan
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - Newsfile
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):